Therapeutic potential of a peptide targeting BCL-2 cell guardians in cancer
- Author(s)
- Adams, JM;
- Details
- Publication Year 2012-06,Volume 122,Issue #6,Page 1965-1967
- Journal Title
- JOURNAL OF CLINICAL INVESTIGATION
- Publication Type
- Journal Article
- Abstract
- A promising approach to cancer therapy is to elicit apoptosis with "BH3 mimetic" drugs, which target proteins of the BCL-2 family. As of yet, however, such drugs can target only certain BCL-2 family proteins. Hence, in this issue of the JCI, LaBelle et al. assess instead the therapeutic potential of a "stapled" BH3 peptide from the BIM protein, which inactivates all its prosurvival relatives. The peptide killed cultured hematologic tumor cells and abated growth of a leukemia xenograft, without perturbing the hematopoietic compartment. Hence, such peptides might eventually provide a new way to treat refractory leukemias.
- Publisher
- AMER SOC CLINICAL INVESTIGATION INC
- Keywords
- PROTEINS; ACTIVATION; APOPTOSIS; INHIBITOR
- Research Division(s)
- Molecular Genetics Of Cancer
- Link To PubMed Central Version
- http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3366422/
- Publisher's Version
- https://doi.org/10.1172/JCI64120
- Terms of Use/Rights Notice
- Copyright © 2012, American Society for Clinical Investigation
Creation Date: 2012-06-01 12:00:00